In July, Professor Hill announced that initial trials on 1,077 UK adults showed the Oxford vaccine induces strong antibody and T cell responses, potentially offering a “double defense” against the coronavirus. Antibodies can repel the virus, while T lymphocytes, a type of white blood cell, help target infected cells.
During testing, 90% of recipients were shown to have developed neutralizing antibodies after a dose of the vaccine, prompting ministers to order 190 million doses of the Covid-19 vaccine, of which 100 million are the Oxford version. .
Also in July, Professor Hill said he had worked with a US campaign group called “1 Day Sooner” to obtain medical-grade doses of Sars-CoV2, the virus that causes Covid-19, which would be needed to human provocation trials. .
The group is made up of more than 30,000 potential volunteers in 140 countries who say they are ready to participate in challenge studies.
A spokesperson for the University of Oxford said: “We do not plan to test the Oxford vaccine in challenge models at this time as we have extensive international clinical trials to evaluate the Oxford vaccine in a real setting. Challenge studies could be very useful in understanding the biology of the disease and better understanding post-infection immunity, if it can be done safely – and groundwork to think about how these studies might be conducted. safely would be useful for any future study.